載入...
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
New treatment options especially of solid tumors including for metastasized prostate cancer (PCa) are urgently needed. Recent treatments of leukemias with chimeric antigen receptors (CARs) underline their impressive therapeutic potential. However CARs currently applied in the clinics cannot be repea...
Na minha lista:
發表在: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2017
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5458214/ https://ncbi.nlm.nih.gov/pubmed/28404896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15572 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|